Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Visual field defect associated with vigabatrin: observational cohort study.

× No keyword cloud information.

3 in total

Review 1. Prescription-event monitoring--recent progress and future horizons.

Authors: R D Mann
Journal: Br J Clin Pharmacol Date: 1998-09 Impact factor: 4.335

2. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.

Authors: R Mackenzie; A Klistorner
Journal: BMJ Date: 1998-01-17

3. Severe persistent visual field constriction associated with vigabatrin.

Authors: T Eke; J F Talbot; M C Lawden
Journal: BMJ Date: 1997-01-18

3 in total

11 in total

1. Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.

Authors: I F Comaish; C Gorman; N R Galloway
Journal: BMJ Date: 2000-05-20

2. Vigabatrin and retinal changes.

Authors: Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal: Doc Ophthalmol Date: 2002-03 Impact factor: 2.379

3. Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.

Authors: Wynne K Schiffer; Douglas Marsteller; Stephen L Dewey
Journal: Psychopharmacology (Berl) Date: 2003-04-09 Impact factor: 4.530

4. Visual field and electrophysiological abnormalities due to vigabatrin.

Authors: Kors van der Torren; Hellen S Graniewski-Wijnands; B C P Polak
Journal: Doc Ophthalmol Date: 2002-03 Impact factor: 2.379

5. Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.

Authors: R M Martin; S Shakir
Journal: Drug Saf Date: 2001 Impact factor: 5.606

Review 6. Adverse reactions to new anticonvulsant drugs.

Authors: I C Wong; S D Lhatoo
Journal: Drug Saf Date: 2000-07 Impact factor: 5.606

7. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study.

Authors: R M Martin; P Biswas; R D Mann
Journal: Br J Clin Pharmacol Date: 2000-07 Impact factor: 4.335

8. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study.

Authors: Deborah Layton; Jane Riley; Lynda V Wilton; Saad A W Shakir
Journal: Br J Clin Pharmacol Date: 2003-02 Impact factor: 4.335

9. Use and safety profile of antiepileptic drugs in Italy.

Authors: M L Iorio; U Moretti; S Colcera; L Magro; I Meneghelli; D Motola; A L Rivolta; F Salvo; G P Velo
Journal: Eur J Clin Pharmacol Date: 2007-02-16 Impact factor: 2.953

Review 10. Visual field defects with vigabatrin: epidemiology and therapeutic implications.

Authors: R Kälviäinen; I Nousiainen
Journal: CNS Drugs Date: 2001 Impact factor: 6.497